In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
OPM Navigates AI Governance Through People
OPM's Taka Ariga explores AI's role in an efficient federal workforce and operations, focusing on trust, data integrity and storytelling.
19m listen -
HHS CIO Eyes Special Cyber Measures to Secure Data
Data security and customer experience are top priorities for Jennifer Wendel, the newly confirmed permanent CIO at the Department of Health and Human Services (HHS).
25m listen -
Coming Soon: AI GovCast Season 2 Explores Federal Artificial Intelligence
The first season of AI GovCast brought listeners the voices at the forefront of government's AI revolution. Coming Jan. 14, season two will dive deeper into AI governance, use cases and implementation.
1m listen -
CMS Cyber Integration Center Leverages PenTesting to Protect Patient Data
Testing efforts help better identify vulnerabilities, coordinate incident response and mitigate risks.
15m listen
